* 10% of trials make it on time * 30% of total trial length = average time overrun.
we have a 1.5 mo overrun in a 12 mo trial, or something like 10% overrun.
the other thing is we have 2 possible announcements in the near future, both of which would mean big things for the valuation. Thats unusual for market cap of $40m
(incidentally results for the 3rd, Smoke Cess, are due this year, the trial is running Feb to Nov according to CT.gov)
re news. what exactly do you want Greg Collier to release to the market? They have 32 people in the Lupus study and there are a multitude of things that can happen with volunteers. Clinical trials are not about timing so much as following process, not f*n it up with the FDA, and keeping your volunteers showing up for their injections.
As long as Glass is on board, you know that's probably in the best hands possible. No news is good news.
So, regardless, its still a question of being patient and waiting for results.
as for finances, I really don't care if they raise at a discount. As long as they are on track, we are talking about a potential 300% increase to the price with one successful trial.
IVX Price at posting:
9.0¢ Sentiment: LT Buy Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)